Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study

Blood neurofilament light levels segregate treatment effects in multiple sclerosis

(2020) Bénédicte Delcoigne et al.   NEUROLOGY

Serum neurofilament light levels in normal aging and their association with morphologic brain changes

(2020) Michael Khalil et al.   Nature Communications

Confounding effect of blood volume and body mass index on blood neurofilament light chain levels

(2020) Ali Manouchehrinia et al.   Annals of Clinical and Translational Neurology

Neurofilaments: The C-Reactive Protein of Neurology

(2020) Kate L. Lambertsen et al.   Brain Sciences

Plasma neurofilament light levels are associated with the risk of disability in multiple sclerosis

(2020) Ali Manouchehrinia et al.   NEUROLOGY

Treatment of Multiple Sclerosis: A Review

(2020) Stephen L. Hauser et al.   AMERICAN JOURNAL OF MEDICINE

Ofatumumab versus Teriflunomide in Multiple Sclerosis

(2020) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort study

(2020) Stefan Bittner et al.   EBioMedicine

Temporal profile of serum neurofilament light in multiple sclerosis: Implications for patient monitoring

(2020) Peter A Calabresi et al.   Multiple Sclerosis Journal

Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease

(2019) Oliver Preische et al.   NATURE MEDICINE

Blood neurofilament light chain as a biomarker of MS disease activity and treatment response

(2019) Jens Kuhle et al.   NEUROLOGY

Blood neurofilament light as a potential endpoint in Phase 2 studies in MS

(2019) Maria Pia Sormani et al.   Annals of Clinical and Translational Neurology

Profiling individual clinical responses by high-frequency serum neurofilament assessment in MS

(2019) Katja Akgün et al.   Neurology-Neuroimmunology & Neuroinflammation

Blood neurofilament light chain at the doorstep of clinical application

(2019) David Leppert et al.   Neurology-Neuroimmunology & Neuroinflammation

Head-to-head drug comparisons in multiple sclerosis

(2019) Carmen Tur et al.   NEUROLOGY

Molecular biomarkers in multiple sclerosis

(2019) Tjalf Ziemssen et al.   Journal of Neuroinflammation

Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis

(2018) Christian Barro et al.   BRAIN

OUP accepted manuscript

(2018)   BRAIN

Neurofilament levels, disease activity and brain volume during follow-up in multiple sclerosis

(2018) Irene Håkansson et al.   Journal of Neuroinflammation

Neurofilaments as biomarkers in neurological disorders

(2018) Michael Khalil et al.   Nature Reviews Neurology

Validation of the Swedish multiple sclerosis register

(2018) P Alping et al.   EPIDEMIOLOGY

Neurofilament light chain serum levels correlate with 10‐year MRI outcomes in multiple sclerosis

(2018) Tanuja Chitnis et al.   Annals of Clinical and Translational Neurology

New insights into the burden and costs of multiple sclerosis in Europe: Results for Switzerland

(2017) Pasquale Calabrese et al.   Multiple Sclerosis Journal

Monitoring disease activity in multiple sclerosis using serum neurofilament light protein

(2017) Lenka Novakova et al.   NEUROLOGY

New insights into the burden and costs of multiple sclerosis in Europe: Results for Switzerland

(2017) Pasquale Calabrese et al.   Multiple Sclerosis Journal

Long-term evolution of multiple sclerosis disability in the treatment era

(2016) et al.   ANNALS OF NEUROLOGY

The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options

(2016) Giulio Disanto et al.   PLoS One

Evaluation of No Evidence of Disease Activity in a 7-Year Longitudinal Multiple Sclerosis Cohort

(2015) Dalia L. Rotstein et al.   JAMA Neurology

Defining the clinical course of multiple sclerosis: The 2013 revisions

(2014) F. D. Lublin et al.   NEUROLOGY

Smoking and multiple sclerosis susceptibility

(2013) Anna Karin Hedström et al.   EUROPEAN JOURNAL OF EPIDEMIOLOGY

A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis

(2011) Carolina Holmén et al.   Multiple Sclerosis Journal

Uncertain BENEFIT of early interferon beta-1b treatment

(2009) Sean J Pittock   LANCET NEUROLOGY

Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial

(2009) Ludwig Kappos et al.   LANCET NEUROLOGY